Healthcare and Energy Sectors Underperforming
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 20 2026
0mins
Should l Buy PODD?
Source: NASDAQ.COM
- Healthcare Sector Struggles: As of midday Friday, healthcare stocks are underperforming, with Insulet Corp (PODD) and Agilent Technologies, Inc. (A) down 3.1% and 2.8%, respectively, indicating a weak trend that may affect investor confidence in the sector.
- ETF Performance Insight: The Health Care Select Sector SPDR ETF (XLV), which tracks the healthcare sector, is down 0.3% on the day but up 1.28% year-to-date, highlighting a contradiction between short-term volatility and long-term growth that could influence investor asset allocation decisions.
- Energy Sector Also Weak: The energy sector is similarly not showing significant gains, with Exxon Mobil Corp (XOM) and Coterra Energy Inc (CTRA) down 2.5% and 2.0%, respectively, reflecting market caution towards energy stocks that may impact future investment inflows.
- ETF Comparison: The Energy Select Sector SPDR ETF (XLE), closely tracking energy stocks, is down 0.6% on the day but up 22.65% year-to-date, indicating that despite short-term fluctuations, the long-term trend remains positive, potentially attracting the attention of long-term investors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PODD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PODD
Wall Street analysts forecast PODD stock price to rise
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 246.610
Low
316.00
Averages
375.83
High
450.00
Current: 246.610
Low
316.00
Averages
375.83
High
450.00
About PODD
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare and Energy Sectors Underperforming
- Healthcare Sector Struggles: As of midday Friday, healthcare stocks are underperforming, with Insulet Corp (PODD) and Agilent Technologies, Inc. (A) down 3.1% and 2.8%, respectively, indicating a weak trend that may affect investor confidence in the sector.
- ETF Performance Insight: The Health Care Select Sector SPDR ETF (XLV), which tracks the healthcare sector, is down 0.3% on the day but up 1.28% year-to-date, highlighting a contradiction between short-term volatility and long-term growth that could influence investor asset allocation decisions.
- Energy Sector Also Weak: The energy sector is similarly not showing significant gains, with Exxon Mobil Corp (XOM) and Coterra Energy Inc (CTRA) down 2.5% and 2.0%, respectively, reflecting market caution towards energy stocks that may impact future investment inflows.
- ETF Comparison: The Energy Select Sector SPDR ETF (XLE), closely tracking energy stocks, is down 0.6% on the day but up 22.65% year-to-date, indicating that despite short-term fluctuations, the long-term trend remains positive, potentially attracting the attention of long-term investors.
See More
US Stocks Close Higher on Strong Economic Data
- Strong Economic Data: US December capital goods new orders rose 0.6% month-over-month, exceeding expectations of 0.3%, indicating a rebound in capital spending that boosts market confidence and drives stock prices higher.
- Housing Market Recovery: December housing starts increased by 6.2% month-over-month to 1.404 million, significantly surpassing the expected 1.304 million, suggesting a recovery in the housing market that could stimulate investment and consumption in related sectors.
- Manufacturing Production Growth: January manufacturing production rose by 0.6% month-over-month, stronger than the expected 0.4%, marking the largest increase in 11 months, indicating a recovery in manufacturing that supports overall economic growth expectations.
- Optimistic Stock Market Performance: Over 75% of S&P 500 companies reported earnings that beat expectations, with Q4 earnings growth projected at 8.4%, providing strong support for the stock market despite lingering doubts about future interest rate policies.
See More
Insulet Corporation Reports Strong Q4 2025 Earnings with Continued Growth
- Sustained Growth: Insulet reported $784 million in revenue for Q4 2025, reflecting a 29% year-over-year increase, marking the tenth consecutive year of over 20% revenue growth, showcasing its robust recurring revenue model and profitability.
- Market Expansion: The company achieved record new customer starts for Omnipod 5 in both U.S. and international markets, particularly in the type 2 diabetes segment, with the prescriber base expanding by 62% to over 6,500 clinicians, underscoring its leadership in diabetes management.
- Increased R&D Investment: R&D spending surged by 50% in Q4 2025, with plans to further increase investments in 2026 to advance next-generation platforms, including Omnipod 6 and a fully closed-loop system, aimed at enhancing patient experience and clinical outcomes.
- Optimistic Outlook: Insulet expects Omnipod revenue to grow by 21% to 23% in 2026, with total company revenue projected to increase by 20% to 22%, alongside an anticipated adjusted EPS growth of over 25%, reflecting strong confidence in future growth.
See More
Insulet Reports Strong Q4 Earnings and 2026 Guidance
- Strong Performance: Insulet's fourth-quarter adjusted earnings reached $1.55 per share, surpassing the market expectation of $1.45, demonstrating the company's robust profitability and competitive position in the market.
- Significant Sales Growth: The company reported sales of $783.8 million, a 31.2% year-over-year increase, and a 29% rise in constant currency, exceeding the market consensus of $768.69 million, indicating strong demand for its products.
- Expanded Buyback Plan: Insulet's board approved a $350 million increase in share repurchase authorization, with approximately $300 million expected to be allocated for repurchases in Q1 2026, reflecting the company's strong financial flexibility and sound financial health.
- Optimistic 2026 Outlook: Insulet forecasts 2026 sales between $3.250 billion and $3.304 billion, representing a year-over-year growth of 20%-22%, with plans for Omnipod products to grow by 21%-23%, showcasing the company's confidence in future market opportunities.
See More
Insulet Surges After Beating Q4 2025 Earnings Forecasts
- Earnings Beat: Insulet (PODD) reported Q4 2025 revenue of $783.8 million, a 29% YoY increase, surpassing consensus estimates by $15.1 million, indicating robust market performance.
- Sales Growth: Revenue from the Omnipod insulin pump surged approximately 42% in the U.S. and 28% internationally, reaching $567.8 million and $214.0 million respectively, reflecting strong global demand for the product.
- Profitability Improvement: Adjusted diluted EPS rose about 35% YoY to $1.55, beating consensus by $0.09, while adjusted operating margin increased to 19%, up 30 basis points from the previous year, showcasing enhanced profitability.
- Positive Outlook: Insulet forecasts adjusted EPS of $4.97 and revenue of $2.7 billion for 2025, representing YoY growth of approximately 54% and 30%, respectively, with continued strong growth expected into 2026, highlighting a favorable market outlook.
See More
US Stock Markets Rise on Strong Economic Data
- Strong Economic Data: US December capital goods new orders rose 0.6% month-over-month, surpassing expectations of 0.3%, indicating a rebound in capital spending and boosting market confidence in economic recovery.
- Housing Market Recovery: December housing starts increased by 6.2% month-over-month to 1.404 million, significantly exceeding expectations of 1.304 million, suggesting a revival in the real estate market that could drive growth in related sectors.
- Manufacturing Production Growth: January manufacturing production rose 0.6% month-over-month, beating expectations of 0.4%, marking the largest increase in 11 months, which indicates a recovery momentum in manufacturing that may further propel economic growth.
- Optimistic Corporate Earnings: Over 75% of S&P 500 companies reported earnings that exceeded expectations, with Q4 earnings growth projected at 8.4%, which will further boost market sentiment and attract investor interest.
See More
Healthcare and Energy Sectors Underperforming
- Healthcare Sector Struggles: As of midday Friday, healthcare stocks are underperforming, with Insulet Corp (PODD) and Agilent Technologies, Inc. (A) down 3.1% and 2.8%, respectively, indicating a weak trend that may affect investor confidence in the sector.
- ETF Performance Insight: The Health Care Select Sector SPDR ETF (XLV), which tracks the healthcare sector, is down 0.3% on the day but up 1.28% year-to-date, highlighting a contradiction between short-term volatility and long-term growth that could influence investor asset allocation decisions.
- Energy Sector Also Weak: The energy sector is similarly not showing significant gains, with Exxon Mobil Corp (XOM) and Coterra Energy Inc (CTRA) down 2.5% and 2.0%, respectively, reflecting market caution towards energy stocks that may impact future investment inflows.
- ETF Comparison: The Energy Select Sector SPDR ETF (XLE), closely tracking energy stocks, is down 0.6% on the day but up 22.65% year-to-date, indicating that despite short-term fluctuations, the long-term trend remains positive, potentially attracting the attention of long-term investors.
See More
US Stocks Close Higher on Strong Economic Data
- Strong Economic Data: US December capital goods new orders rose 0.6% month-over-month, exceeding expectations of 0.3%, indicating a rebound in capital spending that boosts market confidence and drives stock prices higher.
- Housing Market Recovery: December housing starts increased by 6.2% month-over-month to 1.404 million, significantly surpassing the expected 1.304 million, suggesting a recovery in the housing market that could stimulate investment and consumption in related sectors.
- Manufacturing Production Growth: January manufacturing production rose by 0.6% month-over-month, stronger than the expected 0.4%, marking the largest increase in 11 months, indicating a recovery in manufacturing that supports overall economic growth expectations.
- Optimistic Stock Market Performance: Over 75% of S&P 500 companies reported earnings that beat expectations, with Q4 earnings growth projected at 8.4%, providing strong support for the stock market despite lingering doubts about future interest rate policies.
See More
Insulet Corporation Reports Strong Q4 2025 Earnings with Continued Growth
- Sustained Growth: Insulet reported $784 million in revenue for Q4 2025, reflecting a 29% year-over-year increase, marking the tenth consecutive year of over 20% revenue growth, showcasing its robust recurring revenue model and profitability.
- Market Expansion: The company achieved record new customer starts for Omnipod 5 in both U.S. and international markets, particularly in the type 2 diabetes segment, with the prescriber base expanding by 62% to over 6,500 clinicians, underscoring its leadership in diabetes management.
- Increased R&D Investment: R&D spending surged by 50% in Q4 2025, with plans to further increase investments in 2026 to advance next-generation platforms, including Omnipod 6 and a fully closed-loop system, aimed at enhancing patient experience and clinical outcomes.
- Optimistic Outlook: Insulet expects Omnipod revenue to grow by 21% to 23% in 2026, with total company revenue projected to increase by 20% to 22%, alongside an anticipated adjusted EPS growth of over 25%, reflecting strong confidence in future growth.
See More
Insulet Reports Strong Q4 Earnings and 2026 Guidance
- Strong Performance: Insulet's fourth-quarter adjusted earnings reached $1.55 per share, surpassing the market expectation of $1.45, demonstrating the company's robust profitability and competitive position in the market.
- Significant Sales Growth: The company reported sales of $783.8 million, a 31.2% year-over-year increase, and a 29% rise in constant currency, exceeding the market consensus of $768.69 million, indicating strong demand for its products.
- Expanded Buyback Plan: Insulet's board approved a $350 million increase in share repurchase authorization, with approximately $300 million expected to be allocated for repurchases in Q1 2026, reflecting the company's strong financial flexibility and sound financial health.
- Optimistic 2026 Outlook: Insulet forecasts 2026 sales between $3.250 billion and $3.304 billion, representing a year-over-year growth of 20%-22%, with plans for Omnipod products to grow by 21%-23%, showcasing the company's confidence in future market opportunities.
See More
Insulet Surges After Beating Q4 2025 Earnings Forecasts
- Earnings Beat: Insulet (PODD) reported Q4 2025 revenue of $783.8 million, a 29% YoY increase, surpassing consensus estimates by $15.1 million, indicating robust market performance.
- Sales Growth: Revenue from the Omnipod insulin pump surged approximately 42% in the U.S. and 28% internationally, reaching $567.8 million and $214.0 million respectively, reflecting strong global demand for the product.
- Profitability Improvement: Adjusted diluted EPS rose about 35% YoY to $1.55, beating consensus by $0.09, while adjusted operating margin increased to 19%, up 30 basis points from the previous year, showcasing enhanced profitability.
- Positive Outlook: Insulet forecasts adjusted EPS of $4.97 and revenue of $2.7 billion for 2025, representing YoY growth of approximately 54% and 30%, respectively, with continued strong growth expected into 2026, highlighting a favorable market outlook.
See More
US Stock Markets Rise on Strong Economic Data
- Strong Economic Data: US December capital goods new orders rose 0.6% month-over-month, surpassing expectations of 0.3%, indicating a rebound in capital spending and boosting market confidence in economic recovery.
- Housing Market Recovery: December housing starts increased by 6.2% month-over-month to 1.404 million, significantly exceeding expectations of 1.304 million, suggesting a revival in the real estate market that could drive growth in related sectors.
- Manufacturing Production Growth: January manufacturing production rose 0.6% month-over-month, beating expectations of 0.4%, marking the largest increase in 11 months, which indicates a recovery momentum in manufacturing that may further propel economic growth.
- Optimistic Corporate Earnings: Over 75% of S&P 500 companies reported earnings that exceeded expectations, with Q4 earnings growth projected at 8.4%, which will further boost market sentiment and attract investor interest.
See More
